Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study

Hezzell, M J; Boswood, A; Lopez-Alvarez, J; Lotter, N S; Elliott, J

Abstract

Spironolactone improves outcome in dogs with advanced myxomatous mitral valve disease (MMVD). Its efficacy in preclinical MMVD is unknown. The hypothesis was the administration of spironolactone to dogs with compensated MMVD demonstrating risk factors for poorer prognosis will decrease the rate of disease progression. The aim was to provide pilot data to evaluate preliminary effects and sample size calculation for a definitive clinical trial.

Citation

Hezzell, M. J., Boswood, A., Lopez-Alvarez, J., Lotter, N. S., & Elliott, J. (2017). Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study. Journal of Veterinary Cardiology, 19(4), 325-328. https://doi.org/10.1016/j.jvc.2017.06.001

• Journal Article Type: Article
• Acceptance Date: Jun 15, 2017
• Publication Date: Jul 19, 2017
• Deposit Date: Aug 22, 2017
• Publicly Available Date: Aug 1, 2018
• Journal: Journal of Veterinary Cardiology
• Print ISSN: 1760-2734
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 19
• Issue: 4
• Pages: 325-328
• DOI: https://doi.org/10.1016/j.jvc.2017.06.001
• Public URL: https://rvc-repository.worktribe.com/output/1391211